Company Overview - China SXT Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (TCMPs) and TCM Homologous Supplements (TCMHS) [7] - The company was founded in 2005 and is headquartered in Taizhou City, Jiangsu Province, China [7] Offering Details - Univest Securities, LLC announced the closing of a registered direct offering of approximately $10 million for China SXT Pharmaceuticals [1] - The offering involved the sale of 66,666,666 Class A ordinary shares at a purchase price of $0.15 per share [2] - The gross proceeds from the offering were approximately $10 million, with Univest acting as the sole placement agent [3] Regulatory Compliance - The registered direct offering was made under a shelf registration statement on Form F-3, which became effective on December 1, 2025 [4]

TAIZHOU, China, Jan. 08, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced the launch of a Strategic Artificial Intelligence (AI) Insights ...

Core Viewpoint - China SXT Pharmaceuticals, Inc. has regained compliance with Nasdaq's Minimum Bid Price Requirement after a share consolidation and has closed the matter with Nasdaq [1][4]. Group 1: Compliance Notification - The company received a Compliance Notice from Nasdaq on March 13, 2025, confirming it has met the Minimum Bid Price Requirement [1]. - Previously, on October 3, 2024, the company was notified of its failure to maintain a minimum bid price of US$1.00 per share for 30 consecutive business days [2]. - The company was given until April 1, 2025, to regain compliance under Nasdaq Listing Rules [2]. Group 2: Share Consolidation - To address the Minimum Bid Price deficiency, the company executed a share consolidation on February 25, 2025, consolidating every eight ordinary shares into one [3]. - Following the consolidation, the company achieved a closing bid price of at least US$1.00 per share for 10 consecutive business days from February 25, 2025, to March 12, 2025 [4]. Group 3: Company Overview - China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou City, Jiangsu Province, China [5]. - The company specializes in the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (TCMPs) and TCM Homologous Supplements (TCMHS) [5].